Literature DB >> 30191038

Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?

Susanna V Ulahannan1,1, Austin G Duffy2,2.   

Abstract

Entities:  

Keywords:  CTLA-4 inhibitor; PD-1 inhibitor; RFA; TACE; check point inhibitors; hepatocellular carcinoma; immune tharapy; radiofrequency ablation; transcatheter arterial chemoembolization

Year:  2016        PMID： 30191038      PMCID： PMC6095150          DOI： 10.2217/hep-2016-0008

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


× No keyword cloud information.
  17 in total

1.  PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.

Authors:  Feng Shi; Ming Shi; Zhen Zeng; Rui-Zhao Qi; Zhen-Wen Liu; Ji-Yuan Zhang; Yong-Ping Yang; Po Tien; Fu-Sheng Wang
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 2.  The yin and yang of evasion and immune activation in HCC.

Authors:  Oxana V Makarova-Rusher; José Medina-Echeverz; Austin G Duffy; Tim F Greten
Journal:  J Hepatol       Date:  2015-02-27       Impact factor: 25.083

3.  Emerging trends in hepatocellular carcinoma incidence and mortality.

Authors:  Basile Njei; Yaron Rotman; Ivo Ditah; Joseph K Lim
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

Review 4.  Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response.

Authors:  Jonathan I Huz; Marcovalerio Melis; Umut Sarpel
Journal:  HPB (Oxford)       Date:  2012-05-15       Impact factor: 3.647

5.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

6.  [Studies on cases of spontaneous regression of cancer in Japan in 2011, and of hepatic carcinoma, lung cancer and pulmonary metastases in the world between 2006 and 2011].

Authors:  Takeshi Iwanaga
Journal:  Gan To Kagaku Ryoho       Date:  2013-11

Review 7.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

Authors:  Jordi Bruix; Maria Reig; Morris Sherman
Journal:  Gastroenterology       Date:  2016-01-12       Impact factor: 22.682

8.  Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response.

Authors:  Alessandro Zerbini; Massimo Pilli; Diletta Laccabue; Guido Pelosi; Atim Molinari; Elisa Negri; Simona Cerioni; Francesco Fagnoni; Paolo Soliani; Carlo Ferrari; Gabriele Missale
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

Authors:  Bruno Sangro; Carlos Gomez-Martin; Manuel de la Mata; Mercedes Iñarrairaegui; Elena Garralda; Pilar Barrera; Jose Ignacio Riezu-Boj; Esther Larrea; Carlos Alfaro; Pablo Sarobe; Juan José Lasarte; Jose L Pérez-Gracia; Ignacio Melero; Jesús Prieto
Journal:  J Hepatol       Date:  2013-03-04       Impact factor: 25.083
View more
  1 in total

1.  Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic cell maturation and antigen presentation.

Authors:  Zecong Xiao; Tan Li; Xinyao Zheng; Liteng Lin; Xiaobin Wang; Bo Li; Jingjun Huang; Yong Wang; Xintao Shuai; Kangshun Zhu
Journal:  Bioact Mater       Date:  2022-08-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.